Role of previous systemic antibiotic therapy on the probability of recurrence after an initial episode of
Journal
JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
21
01
2023
accepted:
05
03
2023
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
To investigate the role of previous antibiotic therapy in the risk of recurrence after a Multicentre observational study. Patients with a CDI episode achieving clinical cure with oral vancomycin and followed up 8 weeks were included. Previous antibiotic exposure up to 90 days was collected. Multivariate analysis of predictors of recurrence adjusted by the propensity score (PS) of being previously treated with each non-CDI antibiotic was performed. Two hundred and forty-one patients were included; 216 (90%) had received systemic antibiotics. Fifty-three patients (22%) had a CDI recurrence. Rates of recurrence were lower in those treated with piperacillin/tazobactam in the last month when compared with those not receiving piperacillin/tazobactam [3 (7%) versus 50 (25%); Recent use of piperacillin/tazobactam might be associated with a lower risk of CDI recurrence, while recent use of cephalosporins might promote an increased risk. These findings should be considered when treating hospitalized patients.
Identifiants
pubmed: 36968953
doi: 10.1093/jacamr/dlad033
pii: dlad033
pmc: PMC10035639
doi:
Types de publication
Journal Article
Langues
eng
Pagination
dlad033Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
Clin Infect Dis. 2021 Mar 1;72(5):836-844
pubmed: 32069358
JAMA Intern Med. 2016 Dec 01;176(12):1801-1808
pubmed: 27723860
Clin Microbiol Infect. 2016 Aug;22 Suppl 4:S63-81
pubmed: 27460910
Antimicrob Agents Chemother. 2020 Mar 24;64(4):
pubmed: 31964789
Am J Health Syst Pharm. 2019 Apr 17;76(9):581-590
pubmed: 31361830
Lancet Infect Dis. 2018 Mar;18(3):296-307
pubmed: 29273269
Clin Infect Dis. 2018 Mar 19;66(7):987-994
pubmed: 29562266
N Engl J Med. 2015 Apr 16;372(16):1539-48
pubmed: 25875259
Rev Esp Salud Publica. 2013 Jan-Feb;87(1):25-33
pubmed: 23748655
Lancet Infect Dis. 2014 Dec;14(12):1208-19
pubmed: 25455988
Clin Microbiol Infect. 2022 Mar;28(3):321-331
pubmed: 34655745
PLoS One. 2016 Aug 24;11(8):e0161200
pubmed: 27556739
N Engl J Med. 2017 Jan 26;376(4):305-317
pubmed: 28121498
J Antimicrob Chemother. 2017 Apr 1;72(4):1193-1201
pubmed: 27999064
BMC Infect Dis. 2016 Apr 18;16:159
pubmed: 27091232
Clin Microbiol Infect. 2021 Oct;27(10):1448-1454
pubmed: 33878506
J Infect. 2019 Dec;79(6):471-489
pubmed: 31629863
N Engl J Med. 2011 Feb 3;364(5):422-31
pubmed: 21288078
J Antimicrob Chemother. 2012 Mar;67(3):742-8
pubmed: 22146873
Nature. 2022 Nov;611(7937):780-786
pubmed: 36385534
Clin Infect Dis. 2021 Oct 5;73(7):e1579-e1586
pubmed: 33382398
Clin Infect Dis. 2020 Jan 1;70(1):11-18
pubmed: 30820545
Clin Infect Dis. 2016 Mar 1;62(5):574-580
pubmed: 26582748
Clin Infect Dis. 2011 Jul 1;53(1):42-8
pubmed: 21653301
Infect Control Hosp Epidemiol. 2022 Aug;43(8):1067-1069
pubmed: 33958010
Int J Infect Dis. 2022 Nov;124:118-123
pubmed: 36155825
Lancet Infect Dis. 2017 Feb;17(2):194-206
pubmed: 27825595
Clin Infect Dis. 2012 Aug;55 Suppl 2:S154-61
pubmed: 22752865
Antimicrob Resist Infect Control. 2020 Sep 25;9(1):158
pubmed: 32977835
J Antimicrob Chemother. 2014 Apr;69(4):881-91
pubmed: 24324224
Lancet Infect Dis. 2022 Nov;22(11):e336-e340
pubmed: 35617982
Clin Infect Dis. 2011 Sep;53(5):440-7
pubmed: 21844027
N Engl J Med. 2015 Feb 26;372(9):825-34
pubmed: 25714160
Clin Microbiol Infect. 2021 Dec;27 Suppl 2:S1-S21
pubmed: 34678515